T cell responses against Omicron

Originally published May 17, 2022, updated December 1, 2022


Despite a large number of mutations, T cell responses against Omicron is similar to that against other variants, according to authors Jergovic et al. (JI, 2022).

The group from University of Arizona used Mabtech IRIS and FluoroSpot Flex: Human IFN-γ/TNF-α/IL-2/Granzyme B to assess T cell immunity in mRNA vaccine recipients. A slight decrease in IFN-γ/IL-2 double secretors was observed, but IFN-γ/GzB and IFN-γ single secretors remained intact when stimulated with Omicron peptides compared to the ancestral strain.

Interestingly, recipients of three doses mRNA vaccine had better T cell responses than recipients of two doses, supporting the view that three doses should be the recommended regimen.

 

Reference

  • Jergovic et al., T Cell Responses to B.1.1.529 (Omicron) SARS-CoV-2 Variant Induced by COVID-19 Infection and/or mRNA Vaccination Are Largely Preserved, Journal of Immunology 2022

Mabtech products used

  • Mabtech IRIS
  • FluoroSpot Flex: Human IFN-γ/TNF-α/IL-2/Granzyme B


Also available

  • FluoroSpot Plus: Human IFN-γ/Granzyme B/IL-2
  • FluoroSpot Plus: Human IFN-γ/IL-2/TNF-α

Explore similar topics

Highlighted research FluoroSpotVaccines for infectionsSARS-CoV-2PublicationMabtech IRIS